Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson cOVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q4 2024
0
Period ended Dec 29, 2024
Change on a year earlier
–
0 in Q4 2023
History
20 quarters
Since Q1 2020
Sources
15
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Johnson & Johnson COVID-19 Vaccine (Ad26.COV2.S) [reported through FY2024Q4] — U.S. sales ($M) ($M), quarterly Q1 2020–Q4 2024 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug_covid19_us
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.